Multicentric Evaluation of COVID-19 Impact on Cancer Patients' Diagnostic and Management: Set-up of Indicators (COLLAT-COVID)

July 7, 2023 updated by: Hospices Civils de Lyon

Multicentric Evaluation of COVID-19 Impact on Cancer Patients' Diagnostic and Management: Set-up of Indicators to Follow-up the Activities of Different Cancer Pathologies

The COVID-19 pandemic has deeply and globally impacted usual procedures and patients management in cancer centers. The aim of this study is to set-up and collect indicators to follow-up the activities of different cancer pathologies before and during the pandemic. Patients loss' of chance will be analysed in term of diagnosis and access to care (surgery, antineoplastic treatments).

Data collection will focus on the analysis of 2 specific pathologies for French patients in the "Auvergne-Rhône Alpes" Area: peritoneal carcinosis and hepatocellular carcinoma.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

4000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Pierre-Bénite, France, 69495
        • Recruiting
        • Hôpital Lyon Sud, Hospices Civils de Lyon
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients hospitalized in France for peritoneal carcinosis or hepatocellular carcinoma between 2017 and 2020.

Description

Inclusion Criteria:

  • Patients hospitalized in France for peritoneal carcinosis or hepatocellular carcinoma between 2017 and 2020.

Exclusion Criteria:

  • Patients who did not allow the reuse of their medical data for research

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Peritoneal Carcinosis
Patients hospitalized for peritoneal carcinosis between 2017 and 2020.
Other: COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.

The following items will be collected

  • Diagnostic date
  • Diagnostic stage
  • Date of surgery
  • Date of surgery appointment
  • First antineoplastic treatment date
  • Last antineoplastic treatment date
  • Number of treatment cycles recommanded by MDTM
Hepatocellular Carcinoma
Patients hospitalized for hepatocellular carcinoma between 2017 and 2020.
Other: COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.

The following items will be collected

  • Diagnostic date
  • Diagnostic stage
  • Date of surgery
  • Date of surgery appointment
  • First antineoplastic treatment date
  • Last antineoplastic treatment date
  • Number of treatment cycles recommanded by MDTM

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Measure of patient loss of chance when comparing a set of activity indicators between 2020 and the average activities of previous periods (2017-2019)
Time Frame: 24 months
The difference between a set of different activity indicators will be compared between 2020 and the average activities of previous periods (2017-2019)
24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospices Civils de Lyon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2022

Primary Completion (Actual)

December 1, 2022

Study Completion (Estimated)

December 1, 2024

Study Registration Dates

First Submitted

July 4, 2023

First Submitted That Met QC Criteria

July 4, 2023

First Posted (Actual)

July 6, 2023

Study Record Updates

Last Update Posted (Actual)

July 10, 2023

Last Update Submitted That Met QC Criteria

July 7, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 69HCL20_0697

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatocellular Carcinoma

Clinical Trials on COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe